A Study of TAS-120 in Patients With Advanced Solid Tumors

My husband doesn’t qualify for the study as he’s had previous targeted treatment (Pemigatinib), but Hopkins is applying for expanded use of this drug for him.  The drug company already approved; we’re just awaiting FDA and IRB approval.  After 18 months on Pemigatinib, hubby transitioned to the trial for Entinostat with Nivolumab; he had progression on the first 2 scans, so that trial ended for him.  His Hopkins oncologist recommended chemo as the only option for him at that point, but we saw Dr. Goyal in Boston and she recommended expanded use of TAS 120.  Considering his great response to Pemigatinib, she’s hopeful for the TAS 120.